PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, United States of America.\', \'Harvard Medical School, Boston, MA, United States of America.\', \'Department of Medicine, Massachusetts General Hospital, Boston, MA, United States of America.\', \'Department of Pharmacy, Massachusetts General Hospital, Boston, MA, United States of America.\', \'Department of Surgery, Massachusetts General Hospital, Boston, MA, United States of America.\', \'Division of Cardiology, Massachusetts General Hospital, Boston, MA, United States of America.\', \'Faculty of Medicine, University of Balamand, Beirut, Lebanon.\', \'Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.\', \'Fisher Diagnostics, Part of Thermo Fisher Scientific, Middletown, VA, United States of America.\', \'B·R·A·H·M·S GmbH, Part of Thermo Fisher Scientific, Hennigsdorf, Germany.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1371/journal.pone.0262342
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 35025929
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
is ?:relation_isRelatedTo_publication of
?:title
  • Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all